WINTON GROUP Ltd Acquires New Stake in Axon Enterprise, Inc $AXON
by Doug Wharley · The Cerbat GemWINTON GROUP Ltd bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,409 shares of the biotechnology company’s stock, valued at approximately $2,472,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in Axon Enterprise during the fourth quarter worth about $480,000. NewEdge Advisors LLC lifted its holdings in Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after acquiring an additional 668 shares during the last quarter. Empowered Funds LLC boosted its position in shares of Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after purchasing an additional 157 shares in the last quarter. Woodline Partners LP boosted its position in shares of Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in shares of Axon Enterprise in the 2nd quarter worth approximately $284,000. 79.08% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the sale, the president directly owned 296,974 shares in the company, valued at $170,590,774.82. The trade was a 5.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total value of $5,089,900.00. Following the completion of the sale, the chief executive officer directly owned 3,118,012 shares of the company’s stock, valued at approximately $1,587,036,927.88. The trade was a 0.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 66,380 shares of company stock valued at $37,672,266 in the last three months. Insiders own 4.20% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts recently commented on the stock. Barclays increased their target price on shares of Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Needham & Company LLC reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, September 2nd. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. UBS Group raised their price objective on Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Finally, TD Cowen restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, July 22nd. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $721.57.
View Our Latest Stock Report on AXON
Axon Enterprise Trading Up 0.1%
Shares of NASDAQ:AXON opened at $479.34 on Friday. The firm has a fifty day moving average of $561.67 and a two-hundred day moving average of $488.36. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $792.16. The firm has a market capitalization of $38.94 billion, a P/E ratio of 198.90, a price-to-earnings-growth ratio of 9.01 and a beta of 1.40.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The business had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. During the same period in the prior year, the business posted $2.12 earnings per share. Axon Enterprise’s revenue for the quarter was up 35.3% compared to the same quarter last year. On average, equities analysts expect that Axon Enterprise, Inc will post 2.12 EPS for the current fiscal year.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.
The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.
Featured Stories
- Five stocks we like better than Axon Enterprise
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run